The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Danilov D.S.

Sechenov First Moscow State Medical University

Antidepressants — stimulators for the release of norepinephrine and serotonin (history of creation, study of neurochemical effects and classification)

Authors:

Danilov D.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(4): 134‑144

DOI: 10.17116/jnevro2021121041134

Read: 10548 times

Download PDF (RU)
Contact the author
Table of contents

ANTIDEPRESSANTS — STIMULATORS FOR THE RELEASE OF NOREPINEPHRINE AND SEROTONIN (HISTORY OF CREATION, STUDY OF NEUROCHEMICAL EFFECTS AND CLASSIFICATION)
ANTIDEPRESSANTS — STIMULATORS FOR THE RELEASE OF NOREPINEPHRINE AND SEROTONIN (HISTORY OF CREATION, STUDY OF NEUROCHEMICAL EFFECTS AND CLASSIFICATION)

To cite this article:

Danilov DS. Antidepressants — stimulators for the release of norepinephrine and serotonin (history of creation, study of neurochemical effects and classification). S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(4):134‑144. (In Russ.)
https://doi.org/10.17116/jnevro2021121041134

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effect of poly­morphic variants of the HTR2A gene on the effe­ctiveness and safety of sertraline in patients with mixed anxiety-depressive diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):75-84
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Asso­ciations of poly­morphic variants of CYP2C19*2, *17 with effe­ctiveness and safety of sertraline in adolescents with a depressive episode and suicidal tendencies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):12-20
Transcranial electrostimulation as part of combination therapy for mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(1):37-44
Neuropathic pain in chro­nic inflammatory demye­linating poly­neuropathies: analysis of 64 cases. Russian Journal of Pain. 2025;(2):45-53
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411
Effe­cts of corticosterone and anti­depressants fluoxetine and amitriptyline on the expression of neurotrophic factors in rat astrocytoma C6 cells. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(4-2):111-120
Abstract:

The history of the creation and putting into practice of antidepressants and experimental agents — blockers of α2-adrenergic receptors and serotonin 5-HT2-receptors is described. The author analyzes the history of development of mianserin, mirtazapine and other drugs and their position in the classification of antidepressants. On the basis of a generalization of historical facts, the rationality of assigning mianserin, mirtazapine, and possibly other compounds similar in chemical structure and mechanism of action to one neurochemical group and its designation by the term ‘stimulators of the release of norepinephrine and (presumably) serotonin’ is determined.

Keywords:

antidepressants
stimulators of the release of norepinephrine and serotonin
antagonists of α2-adrenergic receptors and serotonin 5-HT2-receptors
mianserin
mirtazapine
setiptilin
classification of antidepressants

Authors:

Danilov D.S.

Sechenov First Moscow State Medical University

Received:

13.02.2020

Accepted:

14.02.2020

Close metadata

References:

  1. Van der Burg WJ, Bonta IL, Delobelle J, et al. A noel type of substituted piperazine with high antiserotonin potency. J Med Chem. 1970;13(1):35-39.  https://doi.org/10.1021/jm00295a010
  2. De Ridder JJ. Mianserin: result of a decade of antidepressant research. Pharm Weekbl Sci. 1982;4(5):139-145.  https://doi.org/10.1007/BF01959033
  3. Kafoe WF, Leonard BE. The effect of a new tetracyclic antidepressant compound, Org GB94, on the turnover of dopamine, noradrenaline and serotonin in the rat brain. Archives Arch Int Pharmacodyn Ther. 1973;206(2):389-391. 
  4. Leonard BE. Some effects of a new tetracyclic antidepressant compound, Org GB94, on the metabolism of monoamines in rat brain. Psychopharmacologia. 1974;36(3):221-236.  https://doi.org/10.1007/bf00421804
  5. Baumann PA, Maître L. Blockade the presynaptic alpha receptor in rat cortex by antidepressants. Experientia. 1975;31:726. 
  6. Baumann PA, Maître L. Blockade of presynaptic alpha-receptors and of amine uptake in the rat brain by the antidepressant mianserine. Naunyn Schmiedebergs Archives Pharmacology. 1977;300(1):31-37.  https://doi.org/10.1007/bf00505077
  7. Doggrell SA. Effect of mianserin on noradrenergic transmission in the rat anococcygeus muscle. Br Jl Pharmacol. 1980;68(2):241-250.  https://doi.org/10.1111/j.1476-5381.1980.tb10413.x
  8. Langer SZ. Presynaptic regulation of catecholamine release. Biochem Pharmacol. 1974;23(13):1793-1800. https://doi.org/10.1016/0006-2952(74)90187-7
  9. Marshall RJ. The pharmacology of mianserin — an update. Br J Clin Pharm. 1983;15(Suppl 2):263-268.  https://doi.org/10.1111/j.1365-2125.1983.tb05874.x
  10. Baldessarini R. Medikamentoznoe lechenie depressii i trevozhnykh rasstrojstv. In: Gilman AG, ed.; Alipov NN, transl. from English. Klinicheskaya farmakologiya po Gudmanu i Gilmanu: rukovodstvo. M.: Praktika; 2006:350-382. (In Russ.).
  11. Vargaftig BB, Coignet JL, de Vos CJ, et al. Mianserin hydrochloride: peripheral and central effects in relation to antagonism against 5-hydroxytryptamine and tryptamine. Eur J Pharmacol. 1971;16(3):336-346.  https://doi.org/10.1016/0014-2999(71)90036-7
  12. Saxena PR, van Houwelingen P, Bonta IL. The effects of mianserin hydrochloride on the vascular responses evoked by 5-hydroxytryptamine and related vasoactive substances. Eur J Pharmacol. 1971;13(3):295-305.  https://doi.org/10.1016/0014-2999(71)90218-4
  13. Maj J. Serotoninergic mechanisms of antidepressant drugs. Psychopharmacol (Berl). 1981;14(1):35-39.  https://doi.org/10.1055/s-2007-1019563
  14. Pettibone DJ, Pflueger AB. Effects of methiothepin and lysergic acid diethylamide on serotonin release in vitro and serotonin synthesis in vivo: possible relation to serotonin autoreceptor function. J Neurochem. 1984;43(1):83-90.  https://doi.org/10.1111/j.1471-4159.1984.tb06681.x
  15. Peroutka SJ, Snyder SH. [3H]Mianserin: differential labeling of serotonin and histamine receptors in rat brain. J Pharmaco Exp Ther. 1981;216(1): 142-148. 
  16. Pazos A, Hoyer D, Palacios JM. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol. 1984;106(3):539-546.  https://doi.org/10.1016/0014-2999(84)90057-8
  17. Hoyer D, Clarke DE, Fozard JR, et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994;46(2):157-203. 
  18. Aizenberg D, Gur S, Zemishlany Z, et al. Mianserin, a 5-HT2a/2c and α2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol. 1997;20(3):210-214.  https://doi.org/10.1097/00002826-199706000-00004
  19. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65(7):927-947.  https://doi.org/10.2165/00003495-200565070-00003
  20. Starke K, Montel H. Involvement of alpha-receptors in clonidine-induced inhibition of transmitter release from central monoamine neurones. Neuropharmacol. 1973;12(11):1073-1080. https://doi.org/10.1016/0028-3908(73)90051-8
  21. Semenova TP, Tiku MK. Vzaimodejstvie serotonin- i noradrenergicheskoj sistem mozga i ego rol’ v regulyatsii povedeniya zhivotnykh. Rossijskij fiziologicheskij zhurnal imeni I.M. Sechenova/Rossijskaya akademiya nauk. 1995;81(8):101-103. (In Russ.).
  22. Raiteri M, Maura G, Versace P. Functional evidence for two stereochemically different α2-adrenoceptors regulating central norepinephrine and serotonin release. J Pharmacol Exp Ther. 1983;24(3):679-684. 
  23. Matsubara S. Desipramine-induced down regulation of beta-adrenergic receptors: effects of noradrenergic and serotonergic neuronal activities and of α2-adrenergic receptor mediated mechanisms. Hokkaido Igaku Zasshi. 1987;62(2):301-310. 
  24. Mongeau R, Blier P, de Montigny C. In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of α2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn Schmiedebergs Archives Pharmacology. 1993;347(3):266-272.  https://doi.org/10.1007/bf00167444
  25. Trendelenburg AU, Trendelenburg M, Starke K, Limberger N. Release-inhibiting α2-adrenoceptors at serotonergic axons in rat and rabbit brain cortex: evidence for pharmacological identity with α2-autoreceptors. Naunyn Schmiedebergs Arch Pharmacol. 1994;349(1):25-33.  https://doi.org/10.1007/BF00178202
  26. Kreiss DS, Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther. 1995;274(2):866-876. 
  27. De Boer TH, Nefkens F, van Helvoirt A, van Delft AM. Differences in modulation of noradrenergic and serotonergic transmission by the α2-adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther. 1996;277(2):852-860. 
  28. Nagayasu K, Kitaichi M, Nishitani N, et al. Chronic effects of antidepressants on serotonin release in rat raphe slice cultures: high potency of milnacipran in the augmentation of serotonin release. Int J Neuropsychopharmacol. 2013;16(10):2295-2306. https://doi.org/10.1017/S1461145713000771
  29. Fink M, Irwin P. Pharmaco-EEG study of 6-azamianserin (ORG 3770): dissociation of EEG and pharmacologic predictors of antidepressant activity. Psychopharmacol (Berl). 1982;78(1):44-48.  https://doi.org/10.1007/bf00470586
  30. De Boer TH, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988;27(4):399-408.  https://doi.org/10.1016/0028-3908(88)90149-9
  31. Westenberg HG. Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60(Suppl 17):4-8. 
  32. De Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995;10(Suppl 4):19-23.  https://doi.org/10.1097/00004850-199512004-00004
  33. De Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57(Suppl 4):19-25. 
  34. Berendsen HH, Broekkamp CL. Indirect in vivo 5-HT1A-agonistic effects of the new antidepressant mirtazapine. Psychopharmacol (Berl). 1997; 133(3):275–282.  https://doi.org/10.1007/s002130050402
  35. Morozov PV. Clinical features of mirtazapine (remeron) action. Psikhiatriya i psikhofarmakoterapiya. 2005;7(4):223-225. (In Russ.).
  36. Carley DW, Radulovacki M. Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat. Am J Respir Crit Care Med. 1999;160(6):1824-1829. https://doi.org/10.1164/ajrccm.160.6.9902090
  37. Millan MJ, Gobert A, Rivet JM, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000;12(3):1079-1095. https://doi.org/10.1046/j.1460-9568.2000.00982.x
  38. Bengtsson HJ, Kele J, Johansson J, Hjorth S. Interaction of the antidepressant mirtazapine with α2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2000;362(4-5):406-412.  https://doi.org/10.1007/s002100000294
  39. Nagayasu K, Kitaichi M, Nishitani N, et al. Chronic effects of antidepressants on serotonin release in rat raphe slice cultures: high potency of milnacipran in the augmentation of serotonin release. Int J Neuropsychopharmacol. 2013;16(10):2295-2306. https://doi.org/10.1017/S1461145713000771
  40. Gillman PK. A systematic review of the serotonergic effects of mirtazapine: implications for its dual action status. Hum Psychopharmacol. 2006; 21(2):117-125.  https://doi.org/10.1002/hup.750
  41. De Boer T, Nefkens F, van Helvoirt A. The α2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol. 1994;253(1-2):5-6.  https://doi.org/10.1016/0014-2999(94)90778-1
  42. Devoto P, Flore G, Pira L, et al. Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Eur J Pharmacol. 2004;487(1-3):105-111.  https://doi.org/10.1016/j.ejphar.2004.01.018
  43. Morita M, Nakayama K. Mirtazapine in combination with perospirone synergistically enhances dopamine release in the rat prefrontal cortex via 5-HT1A receptor activation. Psychiatry Clin Neurosci. 2011;65(3):246-253.  https://doi.org/10.1111/j.1440-1819.2011.02191.x
  44. Medvedev VE. Mirtazonal (mirtazapine) in psychiatric practice: forgotten and new possibilities. V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2011;(4):48-53. (In Russ.).
  45. Nakayama K, Sakurai T, Katsu H. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res Bul. 2004;63(3):237-241.  https://doi.org/10.1016/j.brainresbull.2004.02.007
  46. Gillman K. Mirtazapine, a paradigm of mediocre science in a deficient regulatory environment [Internet]. [Last updated 2019 Mar 23]. Accessed January 19, 2021. https://psychotropical.com/mirtazapine-a-paradigm-of-mediocre-science
  47. Nickolson VJ, Wieringa JH, van Delft AM. Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin. Naun Naunyn Schmiedebergs Arch Pharmacol. 1982;319(1):48-55.  https://doi.org/10.1007/bf00491478
  48. Kelder J, Funke C, De Boer T, et al. A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol. 1997;49(4):403-411.  https://doi.org/10.1111/j.2042-7158.1997.tb06814.x
  49. Richelson E, Souder T, Acuna J. Studies on positive and negative mirtazapine at some human brain receptors. In: 150th annual meeting of the American Psychiatric Association: program and abstracts on new research. San Diego: American Psychiatric Association; 1997. NR248.
  50. Wikström HV, Mensonides-Harsema MM, Cremers TI, et al. Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem. 2002;45(15):3280-3285. https://doi.org/10.1021/jm010566d
  51. Briner K, Dodel RC. New approaches to rapid oneset antidepressants. Curr Pharm Des. 1998;4(4):291-302. 
  52. Popov MJu. Sovremennye antidepressanty: klinicheskie perspektivy nejrokhimicheskoj selektivnosti. V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2004; (3):5-8. (In Russ.).
  53. Akhapkin RV, Bukreeva ND, Vazagaeva TI, et al. Proekt klinicheskikh rekomendatsij «Depressivnyi epizod, Rekurrentnoe depressivnoe rasstrojstvo (F32/F33)»: klinicheskie rekomendatsii. Rossijskoe Obshchestvo Psikhiatrov; 2019. Accessed January 19, 2021. https://psychiatr.ru/news/1034
  54. Pinder RM. Designing a new generation of antidepressant drugs. Acta Psychiatr Scand Suppl. 1997;391:7-13. 
  55. Drobizhev MYu, Kikta SV. How to use mirtazapine in clinical practice. Sotsial’naya i klinicheskaya psikhiatriya. 2009;19(3):60-65. (In Russ.).
  56. Drobizhev MYu, Serdyuk OV, Ovchinnikov AA, et al. Pathogenetic and pharmacological approach in the selection of antidepressants. Sotsial’naya i klinicheskaya psikhiatriya. 2014;24(2):86-91. (In Russ.).
  57. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999;60(Suppl 4):4-11. 
  58. Sjunjakov TS. Affektivnye rasstrojstva — mezhdistsiplinarnaya problema. Novye vozmozhnosti v diagnostike, lechenii i profilaktike (obzor materialov konferentsii). Psikhiatriya i psikhofarmakoterapiya. 2012;14(1):69-72. (In Russ.).
  59. Papazisis G, Siafis S, Tzachanis D. Tachyphylaxis to the Sedative Action of Mirtazapine. Am J Case Rep. 2018;19:410-412.  https://doi.org/10.12659/ajcr.908412
  60. Malamood M, Roberts A, Kataria R, et al. Mirtazapine for symptom control in refractory gastroparesis. Drug Des Devel Ther. 2017;11:1035-1041. https://doi.org/10.2147/DDDT.S125743
  61. Shin’on ZhM. Theories, epidemiology and basic principles of treatment of anxiety disorders. Sinaps. 1992;(2):12-31. (In Russ.).
  62. Gubsky YuI, Shapovalova VA, Kutko II, Shapovalov VV. Lekarstvennye sredstva v psikhofarmakologii. Kiev: Zdorov’ya; Kharkov: Torsing; 1997:288. (In Russ.).
  63. Smulevich A.B. Depressii v obshchej meditsine. M.: MIA; 2001:256. (In Russ.).
  64. Yastrebov DV. Mirtazapine’s place among other antidepressants. Psikhiatriya i psikhofarmakoterapiya. 2007;9(5):22-26. (In Russ.).
  65. Smulevich AB. Rasstrojstva lichnosti. Traektoriya v prostranstve psikhicheskoj i somaticheskoj patologii. M.: MIA; 2012:336. (In Russ.).
  66. Pinder RM. Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant? Neuropsychiatr Dis Treat. 2005;1(1):3-7.  https://doi.org/10.2147/nedt.1.1.3.52293
  67. Kozlovsky VL, Popov MYu. Osobennosti provedeniya bazovoj i ad”yuvantnoj terapii antidepressantami v lechenii depressivnogo i trevozhnogo affekta (metodicheskie rekomendatsii). SPb; 2012:22. (In Russ.).
  68. Dmitrieva TB, Krasnov VN, Neznanov NG, et al. Psikhiatriya: natsional’noe rukovodstvo. M.: GEOTAR-Media; 2009:1000. (In Russ.).
  69. Stahl SM. Stahl’s essential psychopharmacology. 4th ed. Cambridge: University Press; 2013:608. 
  70. Gower AJ, Broekkamp CL, Rijk HW, Van Delft AM. Pharmacological evaluation of in vivo tests for alpha 2-adrenoceptor blockade in the central nervous system and the effects of the enantiomers of mianserin and its aza-analog ORG 3770. Arch Int Pharmacodin Ther. 1988;291:185-201. 
  71. Mosolov SN. Klinicheskoe primenenie sovremennykh antidepressantov. SPb: MIA; 1995:564. (In Russ.).
  72. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Printsipy i praktika psikhofarmakoterapii. Kiev: Nika-Tsentr; 1999:728. (In Russ.).
  73. Montgomery S. Why do we need new and improved antidepressants? Medicographia. 2005;27(3):213-216. 
  74. Raevsky KS. Antidepressanty: nejrokhimicheskie aspekty mekhanizma dejstviya. Psikhiatriya i psikhofarmakoterapiya. 2001;3(5):162-166. (In Russ.).
  75. Andrusenko MP. Antidepressanty: sootnoshenie osobennostej nejrokhimicheskogo dejstviya i klinicheskikh effektov pri lechenii depressii. Psikhiatriya i psikhofarmakoterapiya. 2005;7(5):273-279. (In Russ.).
  76. Mosolov SN. Farmakoterapiya psikhicheskikh rasstrojstv. In: Gofman AG, ed. Psikhiatriya: spravochnik prakticheskogo vracha. 2-e ed. M.: MEDpress-inform; 2010:371-445. (In Russ.).
  77. Psikhiatriya: natsional’noe rukovodstvo. Aleksandrovsky YuA, Neznanov NG, chief eds. 2-e izd. M.: GEOTAR-Media. 2018;1008. (In Russ.).
  78. Kozlovsky VL. Psikhotropnye preparaty: ot teorii k praktike. SPb: Spetslit; 2018:175. (In Russ.).
  79. Watthey JW, Gavin T, Desai M, et al. Synthesis and biological properties of thiophene ring analogues of mianserin. J Med Chem. 1983;26(8):1116-1122. https://doi.org/10.1021/jm00362a006
  80. Liebman JM, Lovell RA, Braunwalder A, et al. CGS 7525A, a new, centrally active α2-adrenoceptor antagonist. Life Sci. 1983;32(4):355-363.  https://doi.org/10.1016/0024-3205(83)90081-4
  81. Niho T, Ito C, Shibutani Y, et al. Pharmacological properties of MO-8282, a novel antidepressant. Nippon Yakurigaku Zasshi. 1986;88(4):309-320.  https://doi.org/10.1254/fpj.88.309
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.